Month: September 2021

Financial reports

Years Quarter Interim Registration Document First Second Third Fourth 2023               XBRL(fr)     2022           XBRL(fr) 2021             XBRL(fr) 2020             2019             2018            … Continue reading Financial reports

Key figures

In € million except share and per share data 2022 2021 2020 2019 2018 Revenue 10.3 17.4 9.9 13.7 42.9 R&D Expense -32.2 -32.9 -27.3 -31.4 -27.3 G&A Expense -7.9 -7.4 -6.5 -7.1 -7.0 Net income (loss) -32.8 -19.5 -17.2 -18.8 8.0 Net Cash Burn -22.8 -10.0 -17.0 -20.5 -24.5 Cash & Cash Equivalents 26.8… Continue reading Key figures

produits : 5 OVs teaser

AstraZeneca Transgene and AstraZeneca have entered into a collaboration agreement under which Transgene designs five innovative oncolytic viruses based on the Invir.IO™ platform. AstraZeneca can exercise an option on each of these candidates.

produits : TG6050

TG6050 Induce an immune response against tumors resistant to available treatments TG6050 is an oncolytic virus that has been engineered to express human IL-12 and an anti-CTLA4 antibody. TG6050 has been designed to be administered intravenously. By selectively targeting tumor cells and expressing IL-12 and an anti-CTLA4 antibody in the tumor microenvironment, TG6050 is expected… Continue reading produits : TG6050

produits : BT-001 teaser

BT-001 BT-001 is the first oncolytic virus from Invir.IO™ and is optimized to act as a Trojan horse. This novel immunotherapy approach has been designed to be highly targeted and is based on the patented viral backbone (VVcop TK-RR-). Two specific “weapons” have been integrated into the Vaccinia viral DNA: an anti-CTLA4 antibody, which was… Continue reading produits : BT-001 teaser